RxDoctor Payments Data

Carolyn Goldschmidt, DO

Neuromusculoskeletal Medicine & OMM · Cleveland, OHNPI 1831584754

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $54,212 of the $80,164 with a category attached, or 67.6%. TG Therapeutics, Inc. accounts for 63.5% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $31,500, more than ten times the $719 reported in 2019.

$80,164in general payments, 2019–2025

Across 272 payments — averaging $294.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$51K
  • Sanofi$9K
  • Genentech USA, Inc.$9K
  • Novartis$5K
  • EMD Serono, Inc.$2K
  • Biogen$2K
  • plus $2K from 17 others
$39,010in research payments, 2019–2025

Across 6 payments — averaging $6501.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$22K
  • Biogen$10K
  • TG Therapeutics, Inc.$7K

What the payments were for

  • Consulting fees$12,86016%
  • Speaking & faculty fees$54,21268%
  • Travel & lodging$3,3914%
  • Food & beverage$9,60212%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromusculoskeletal medicine & omm providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$20,721
Medicare patients
99
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab11$95,475
Nurtec OdtRimegepant Sulfate20$22,148
Aimovig AutoinjectorErenumab-Aooe20$14,798
Dalfampridine ErDalfampridine27$10,492
Gabapentin125$1,829
Duloxetine Hcl29$793
Donepezil Hcl34$411
Pregabalin20$356
Baclofen20$347
RizatriptanRizatriptan Benzoate24$264
Sumatriptan Succinate30$230
Amitriptyline Hcl39$225
Topiramate15$207
Cyclobenzaprine Hcl11$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$298$22,14820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other neuromusculoskeletal medicine & omm in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →